Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.44 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL3215035 | 1.00 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL119088 | 0.96 | CA4 (0.47) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL31626822 | 0.96 | CA4 (0.47) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL15845334 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL3216076 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL3205805 | 0.92 | — | — | |
| Glycine SCHEMBL20239641 | 0.92 | — | — | |
| Glycine SCHEMBL20239648 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL15842973 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL20269830 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018111756-A1 | METAL COMPLEXES | NOVUS INTERNATIONAL INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180162803-A1 | METAL COMPLEXES | NOVUS INTERNATIONAL, INC. | 2018-06-14 | — | — | US | disclosed |
| US-7834210-B2 | Hair loss prevention by natural amino acid and peptide complexes | BIODERM RESEARCH (US) | 2010-11-16 | — | — | US | disclosed |
| US-7777073-B2 | Topical delivery system for antiaging and skin whitening agents | BIODERM RESEARCH (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090253668-A1 | Hair Loss Prevention by Natural Amino Acid and Peptide Complexes | BIODERM RESEARCH (US) | 2009-10-08 | — | — | US | disclosed |
| US-7572933-B2 | Skin and hair restoration by natural amino acid peptide complexes | BIODERM RESEARCH (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | BIODERM RESEARCH (US) | 2009-03-19 | — | — | US | disclosed |
| US-20080287536-A1 | Skin and Hair Restoration by Natural Amino Acid and Peptide Crown Complexes | BIODERM RESEARCH (US) | 2008-11-20 | — | — | US | disclosed |
| US-7427690-B2 | Multifunction “crown complexes” from amino acids and peptides for skin and hair restoration | BIODERM RESEARCH (US) | 2008-09-23 | — | — | US | disclosed |
| US-20070099886-A1 | Multifunction \"Crown Complexes\" from Amino Acids and Peptides for Skin and Hair Restoration | BIODERM RESEARCH (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074691-A1 | Topical Delivery System for Antiaging and Skin Whitening Agents | TYR, MMP17, MMP1 | CA4 4402/4885GLRA1 3308/4885SLC6A9 4169/4885 |
| US-20080287536-A1 | Skin and Hair Restoration by Natural Amino Acid and Peptide Crown Complexes | MMP17, MC1R, TYR | CA4 1396/4885GLRA1 2460/4885SLC6A9 3574/4885 |
| US-20090253668-A1 | Hair Loss Prevention by Natural Amino Acid and Peptide Complexes | MMP1, MMP17, MMP13 | CA4 2658/4885GLRA1 1628/4885SLC6A9 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.